French biotech Abivax saw its stock surge over 500% after reporting positive Phase 3 trial results for obefazimod, an oral miRNA-124 enhancer for moderate to severe ulcerative colitis. The pooled remission rates significantly exceeded placebo, with favorable safety profiles observed. With a global study program including more than 1,200 patients across 600 sites, Abivax plans to initiate a maintenance trial and aims for regulatory submissions in 2026. The advancement positions obefazimod among leading potential therapies in inflammatory bowel disease.